Novo Nordisk (NOVOB DC) wegovy pill 25mg showed greater mean weight loss vs. Orforglipron (LLY) 36mg in population-adjusted indirect treatment comparison
Novo Nordisk's Wegovy pill demonstrated superior efficacy in weight loss compared to Eli Lilly's Orforglipron in a population-adjusted comparison, highlighting a potential competitive advantage.
UK Foreign Secratary Cooper says just 5 ships passed through Hormuz in the last 24hrs
Amazon’s (AMZN) AWS and Siemens Energy (ENR GY) team up to advance digital transformation in the energy sector
Novo Nordisk (NOVOB DC) wegovy pill 25mg showed greater mean weight loss vs. Orforglipron (LLY) 36mg in population-adjusted indirect treatment comparison
Brazilian Industrial Production MoM (Feb) M/M 0.9% (Prev. 1.8%)
Brazilian Industrial Production YoY (Feb) Y/Y -0.7% (Prev. 0.2%)
Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.
- Population-adjusted indirect treatment comparison uses data from oasis 4 & attain-1 clinical trials.
- In separate patient preference study, 84% favoured wegovy pill 25mg-like treatment profile vs. Orforglipron-like profile.
- Orforglipron 36mg treatment had about 14 times higher discontinuation odds due to gastrointestinal adverse events vs wegovy pill 25mg.
Additionally, a strong preference among patients for Wegovy, combined with significantly lower discontinuation rates due to side effects, suggests that Novo Nordisk may see enhanced market positioning and demand in the weight loss segment, which could positively impact their revenues.
Related headlines
- Newsquawk Daily European Equity Opening News - 9th September 20268 hours ago
- European Equity pre-Market Summary - 9th September 2026: European bourses are indicative of a slightly softer open; Inditex reports poor results7 hours ago
- US BROKER MOVES: TMO upgraded at UBS; VMC downgraded at Wells Fargo1 hour ago
- US Market Wrap: Stocks fall and crude gains amid escalating geopolitics 17 hours ago
- Merck (MRK) veteran and psychedelics developer tapped for top FDA job17 hours ago
- Newsquawk European Market Wrap - 8th September 202623 hours ago
- US EQUITY OPEN: US indices open in the red amid downbeat risk tone after Labor Day holiday1 day ago
- US PREMARKET MOVERS: NVS, TSLA, UNFI, UBER, INTC, RGTI, AMGN, PTON1 day ago
- Crystler (STLAM IM/STLAP FP) files to recall over 200k US vehicles6 hours ago
- European Movers: Airbus (AIR FP) -1.3%, LVMH (MC FP) -1.3%, Orsted (ORSTED DC) -1.6%, Inditex (ITX SM) -3%, Burberry (BRBY LN) -3%6 hours ago
- DoJ confirms it issues second request for Fox (FOX) and Roku (ROKU) merger with closing expected in H1 '27 27 min ago
- Newsquawk Daily US Equity Opening News: DOW weighs exit from $20b Saudi chemicals venture; GOOG to invest $15bln in Finnish AI infrastructure1 hour ago
- FedEx (FDX) files to sell USD-denominated 10-year notes1 hour ago
- OpenAI is reportedly projecting compute spending of c. USD 750bln through 2030 but still feels "really short" on computing power, NYT reports1 hour ago
- Amazon (AMZN) sets size on debut sterling bond sale at GBP 4.25bln1 hour ago
- JPMorgan’s (JPM) Jamie Dimon to meet with UK Chancellor as bank taxes loom1 hour ago
- Sam Altman privately told a group of GOP economists he does NOT support having the government own shares in OpenAI, reports Washington Sun2 hours ago
- Dow (DOW) reportedly weighs exit from USD 20bln Saudi chemicals venture2 hours ago
- Amazon (AMZN) plans to issue multiple series of sterling-denominated notes2 hours ago
- Uber (UBER) announces EUR 4.5bln bond sale 2 hours ago
The whole workspace, free to try.
Try it free